GLP1R and rheumatoid arthritis: In the RA-diabetes subgroup, there were 15 deaths among 1,367 new users of GLP-1-RAs compared to 219 deaths among 2,913 new users of DPP-4i (weighted IR: 9.3 versus 20.9 deaths per 1,000 person-years; HR: 0.45 [0.22–0.93], RD: -11.6 [-26.3 to 3.0]).